Pharmaceuticals in Thoughts from the Centre

World Alzheimer’s Day

By Mark Steedman, PhD. Manager Centre for Health Solutions

Alzhimer

In the late 1970s, Earth, Wind & Fire released one of their biggest hits – September – with an opening line that has become an internet meme and is widely recognised around the world.

“Do you remember the 21st night of September?”

Continue reading

Posted on 21/09/2018 | 0 Comments

Turbo charge your drug development: How pharma companies should use emerging technologies

by Dr Francesca Properzi PhD

Drug

 We are delighted to use this week’s blog to introduce the Centre’s new Research Manager, Francesca Properzi, who joined the team last week. Here is Francesca’s take on the way emerging technologies can improve pharma R&D.

R&D management in the pharmaceutical industry is facing unprecedented challenges. While the availability of new high-impact technologies has the potential to help reshape research and clinical development, our latest report from our Measuring the return from pharmaceutical innovation series, A new future for R&D?, shows the costs of drug development for 12 large cap pharma companies has increased sharply over the past eight years by nearly 50 per cent, totalling just under $2 billion per drug.  Although a number of therapies are still expected to achieve blockbuster status, lower projected R&D returns are decreasing sharply from a once double digit high to an average of slightly over three per cent. This exceedingly low internal rate of return (IRR), is mostly due to companies paying the price of lower post-approval sales and increased R&D costs.   

Continue reading

Posted on 14/09/2018 | 0 Comments

Digital R&D: Four ways to maximise patient engagement in clinical trials

by Dawn Anderson, Managing Director, Deloitte Consulting LLP

Testtubes

The Deloitte Center for Health Solutions recently interviewed 43 biopharmaceutical industry stakeholders to explore where the industry sees value and opportunities for using digital technologies in the clinical development process; understand reasons behind the relatively slow pace of digital adoption; and uncover strategies to overcome barriers and accelerate the use of digital in clinical trials.

Continue reading

Posted on 17/08/2018 | 0 Comments

Blockchain: Picking the right links for the Life Science and Health Care industries

by Amen Sanghera, Analyst, UK Deloitte Centre for Health Solutions and Rui Zhou, Consultant, Deloitte Canada

Chain

Blockchain is increasingly touted as the technology that could transform many of the challenges facing healthcare and life sciences; whether it is providing secure and interoperable electronic health records (EHR), increasing the integrity of clinical trials data or improving the transparency of life science’s supply chain operations. While, the technology itself is not revolutionary, using it in the right situation, especially where trust, consensus or immutability are essential to the operations of the Life Science and Health care industries, could be transformational.

Continue reading

Posted on 27/07/2018 | 0 Comments

R&D leaders roundtable: the key takeaways to help address pharma’s R&D productivity challenge

by Colin Terry, Partner, Deloitte Consulting

Future-of-rd

Following the launch of our eighth annual report ‘A new future for R&D? Measuring the return from pharmaceutical innovation 2017’, we hosted a peer-to-peer discussion on how R&D leaders can address R&D performance trends. The roundtable stimulated many insightful discussions among the senior R&D executives in attendance, and below are some of the key takeaways that resonated most with me.

Continue reading

Posted on 27/07/2018 | 0 Comments

Five barriers that could keep biosimilar manufacturers from cracking the US market

by James Forsyth, Director, Deloitte MCS Limited, and Cameron McClearn, Principal, Deloitte Consulting LLP

Writing

This week’s blog by James Forsyth (Director Deloitte MCS) and Cameron Mclearn (Principle Deloitte Consulting US) featured on the US Center for Health Solutions blog, A view from the Center, earlier this week.1 The article explores the challenges that are keeping biosimilar manufacturers from gaining more traction in the US market.

Continue reading

Posted on 29/06/2018 | 0 Comments

Emerging technologies can boost performance in clinical trials

by Greg Reh, Vice Chairman, US and Global Life Sciences Leader, Deloitte LLP

Athletes

This week’s blog by Greg Reh, Deloitte’s Global Life Sciences Leader first featured on the US Center for Health Solutions blog, A view from the Center.i In it Greg explores how emerging technologies can improve enrolment in, remove barriers of participation and increase drug adherence in pharma clinical trials.

Continue reading

Posted on 01/06/2018 | 0 Comments

Beyond bitcoin: Five possible uses for blockchain in health care

by Greg Reh

Chains

Blockchain technology is continually touted to revolutionise the operations of every industry it becomes associated with, and for health care and life sciences this no different. This week’s blog, by Greg Reh, Deloitte’s Global Life Sciences and Health Care Leader, discusses the possible use cases blockchain may have in health care. The blog first appeared in on the US Center for Health Solutions website, part of their My Take series.i

Continue reading

Posted on 13/04/2018 | 0 Comments

Tackling counterfeit medicines in India

by Pratik Avhad

Finger-prints

India is one of the leading global producers of low-cost generic medicines due to its high domestic demand and inexpensive manufacturing costs. The country’s pharmaceutical market is the world’s third largest in terms of volume, but the thirteenth largest in value.1 However, counterfeiting is pervasive, with an estimated 20 per cent ($4.3 billion in 2013-14) of India’s drug market comprised of counterfeit drugs.2,3 While counterfeiting is a global issue, it is much more prevalent in low and middle income countries with an estimated 10 to 30 per cent of medicines in these countries being counterfeit, compared to just one per cent of medicines in high-income countries.4

Continue reading

Posted on 06/04/2018 | 0 Comments

As biosimilars enter the US market, will they be used, and can they reduce spending?

by Thomas Croisier and James Forsyth, Deloitte Consulting, LLP

Pills

This week’s blog is by Tomas Croisier and James Forsyth, a partner and director in our life sciences consulting practice, respectively. It was first featured in a blog post on the US Center of Health Solutions site, and explores the impact of biosimilars may have on the treatment of oncology, particularly in the US.1

Continue reading

Posted on 01/03/2018 | 0 Comments